Bellevue Group Ag Summit Therapeutics Inc. Transaction History
Bellevue Group Ag
- $4.31 Billion
- Q1 2025
A detailed history of Bellevue Group Ag transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 67,685 shares of SMMT stock, worth $1.94 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
67,685
Previous 170,594
60.32%
Holding current value
$1.94 Million
Previous $3.05 Million
57.14%
% of portfolio
0.03%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
246Shares Held
84.2MCall Options Held
1.76MPut Options Held
2.43M-
Baker Bros. Advisors LP New York, NY24.4MShares$700 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$249 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$226 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$188 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$139 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.77B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...